Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Buys 111,110 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 111,110 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was bought at an average cost of $9.00 per share, with a total value of $999,990.00. Following the acquisition, the director owned 18,018,546 shares of the company’s stock, valued at approximately $162,166,914. The trade was a 0.62% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.45 per share, with a total value of $779,642.50.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of NASDAQ:BNR opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $3.23 and a twelve month high of $41.72. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. The company has a market cap of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. The company’s 50 day moving average is $12.57 and its 200 day moving average is $20.04.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($2.29) by $2.09. The business had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Institutional Investors Weigh In On Burning Rock Biotech

Several hedge funds have recently modified their holdings of the company. Crcm LP grew its position in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after acquiring an additional 26,809 shares during the period. Prospera Financial Services Inc raised its holdings in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares during the period. Marshall Wace LLP purchased a new position in Burning Rock Biotech during the fourth quarter worth approximately $220,000. Finally, Renaissance Technologies LLC boosted its position in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares in the last quarter. 30.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BNR has been the topic of several recent research reports. Wall Street Zen lowered shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.